| (Values in U.S. Thousands) | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 |
| Sales | 160 | 200 | 200 | 200 | 200 |
| Sales Growth | -20.00% | unch | unch | unch | unch |
| Net Income | -1,650 | -1,760 | -1,670 | -2,550 | -3,020 |
| Net Income Growth | +6.25% | -5.39% | +34.51% | +15.56% | -19.37% |
Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel.
Fiscal Year End Date: 12/31